secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001193125-26-016046
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs expands BGE-102 into diabetic macular edema; Phase 1b/2a trial planned mid-2026
--------------------------------------------------------------------------------

- Plans to initiate Phase 1b/2a proof-of-concept trial in DME in mid-2026; results expected mid-2027.
- Preclinical DME model: oral BGE-102 achieved near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity.
- BGE-102 ongoing Phase 1 shows favorable tolerability and robust reductions in hsCRP, IL-6, and IL-1β.
- Additional milestones: 1H2026 complete Phase 1, start CV risk Phase 2a; 2H2026 CV risk data.
- Cites growing clinical evidence for targeting inflammation in retinal diseases, including intravitreal IL-6 inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526016046/0001193125-26-016046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526016046/bioa-20260120.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-016046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer